Trial Profile
Phase II Study Evaluating the Efficacy of Aflibercept for the Treatment of Choroidal Neovascularization in Angioid Streaks in Young Patients.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 21 Mar 2017
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Angioid streaks; Choroidal neovascularisation
- Focus Therapeutic Use
- Acronyms ASTRID
- 05 Jan 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 16 Oct 2015 New trial record